Evidence map›Paper›PMID 35846037›Full record

ArticleEJHaem2022

First-line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes.

Abraham Avigdor, Fabrizio Trinchese, Francois Gavini, Nawal Bent-Ennakhil, Mehul Dalal, Athanasios Zomas, Sharmeen Gettner Broun, Guido Gini

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abraham AvigdorThe Chaim Sheba Medical Center Institute of Hematology Ramat Gan Israel.ORCID https://orcid.org/0000-0002-7448-869X
Fabrizio TrincheseTakeda Pharmaceuticals International AG Zurich Switzerland.
Francois GaviniTakeda Pharmaceuticals International AG Zurich Switzerland.
Nawal Bent-EnnakhilTakeda Pharmaceuticals International AG Zurich Switzerland.
Mehul DalalMillennium Pharmaceuticals, Inc. A wholly owned subsidiary of Takeda Pharmaceutical Company Ltd Cambridge Massachusetts USA.
Athanasios ZomasTakeda Pharmaceuticals International AG Zurich Switzerland.
Sharmeen Gettner BrounKantar Paris France.ORCID https://orcid.org/0000-0001-5928-6195
Guido GiniOspedali Riuniti di Ancona Clinic of Hematology, Ancona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Classical Hodgkin lymphoma (cHL) is curable in 90% of cases, but advanced stage patients who do not respond well to first-line (1L) therapy have poorer outcomes. This retrospective study examines patient characteristics, treatment patterns, clinical outcomes, and safety management of 1L cHL therapies in common clinical practice in Italy (IT), Israel (IL), and Spain (SP). The overall sample (

Indexed as

Advanced stage Hodgkin's lymphomaclinical outcomefrontline chemotherapyinterim PET scanssafety

Identifiers

PMID35846037
PMCPMC9176002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.